NEW DELHI, India – Princeton, N.J.-based Vyome Therapeutics Inc., which specializes in medicines for treating skin diseases caused by resistant microbes, has announced a $22 million financing for the phase IIb trial of its lead molecule, VB-1953, for treatment of moderate to severe acne.